Enovis Corp (LTS:0I1B)
$ 48.35 -0.10705 (-0.22%) Market Cap: 2.73 Bil Enterprise Value: 4.11 Bil PE Ratio: 0 PB Ratio: 0.82 GF Score: 68/100

Enovis Corp at Robert W Baird Global Healthcare Conference Transcript

Sep 12, 2023 / 12:30PM GMT
Release Date Price: $56.41
Jeffrey D. Johnson
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

All right. Thank you. Good morning. Why don't we get started? My name is Jeff Johnson. I'm the senior medical technology analyst at Baird, and our first presentation this morning is from Enovis Corporation, a leader in the $4 billion Prevention & Recovery markets and in the $38 billion global orthopedic implant market.

With us today from Enovis, we're happy to have CEO, Matt Trerotola; Chief Financial Officer, Ben Berry. And Matt, I'm going to turn it over to you, if you have a few minutes of prepared remarks, and then we'll go straight into Q&A. Thanks.

Matthew L. Trerotola
Enovis Corporation - CEO & Chairman

Yes, sounds good. Thanks. Thanks a lot, Jeff. Hey, everybody. Great to see you. Thanks for being here and for tuning in. Glad to have an opportunity to share a little bit about our company.

I'll start with forward-looking statements comments here. And to introduce our company, we are a MedTech growth company, Enovis.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot